Last updated on October 2019

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)

Brief description of study

The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B], and rituximab in combination with a 4 drug combination of cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone [R-CHOP]) is effective and safe, compared with placebo in combination with standard immunochemotherapy (R-B or R-CHOP) in patients with relapsed iNHL who have received at least one, but at most three, lines of treatment, including rituximab, and/or rituximab biosimilars, and/or anti-CD20 monoclonal antibody based immunochemotherapy and alkylating agents.


Clinical Study Identifier: TX228638

Find a site near you

Start Over

Ironwood Physicians P.C. DBA Ironwood Cancer & Res. Ctr.

Located in: Chandler, Arizona United States
  Connect »